• caenes

The research project 3D-Biopsy by tomosynthesis, in which Baldomero Ventura SL participates, presents its results to ACC1Ó

The Agency for the Competitiveness of the Enterprise (ACCIÓ) accredited in 2016 the technologies applied to health as a RIS3CAT Community.

13 RIS3CAT Communities were promoted with a total budget of 53 million euros, aids managed by ACCIÓ, part of which comes from the European Regional Development Fund (ERDF).

All of them lever an investment in research and innovation of more than 140 million euros. One of them is part of the sectoral scope of the health and life sciences industries.

Within this community, the research, development and innovation project Biopsy 3D by tomosynthesis was selected. Baldomero Ventura participates in this project along with other institutions, such as IDNEO Technologies (FICOSA), the Institute of High Energy Physics (IFAE), UDIAT Diagnostic Center – Parc Taulí Sabadell Foundation, and the National Microelectronics Center (CNM) – Higher Center for Scientific Research (CSIC). The Project aim was to develop innovative products and technologies in the field of biopsy devices that would improve the accuracy of the diagnosis, while allowing optimization of the planning of the treatments to be followed by the patient, thus resulting in greater efficacy and sustainability of hospital resources allocated to therapies and a higher rate of post-treatment recovery of the patient, therefore, a better quality of life for the general population.

The result has been the achieving of a prototype of scientific instruments of interest to the members of the community and by the different agents of the health sector, which allows testing and validating a new technology focused on improving the resolution of the vision of health professionals in the diagnosis of breast pathologies in the prone position. The developed Prototype may become a medical device after its industrialization and regulatory validation phase. Additionally, future business models may be implemented for their exploitation.

RIS3CAT is a research and innovation strategy promoted by the European Commission and approved by the Government of Catalonia that identifies seven leading sectoral areas in which Catalonia has a competitive advantage, such as the health and life sciences industries. It is a commitment to R+D and innovation to encourage economic growth, as well as generate new economic activity and new work places. The RIS3CAT communities are groupings of companies that promote R&D&I action plans in the identified sectorial areas.

An R + D + i project

Developing innovative products and technologies in the field of biopsy devices was the goal of the 3D Biopsy by tomosynthesis project. This initiative aims to achieve a more optimal treatment planning and one of its aims has been to achieve a higher rate of post-treatment recovery for the patient.